Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The p53 tumor suppressor protein is a principal mediator of growth arrest, senescence, and apoptosis in response to a broad array of cellular damage. p53 is a substrate for the ubiquitin-proteasome system, however, the ubiquitin-conjugating enzymes (E2s) involved in p53 ubiquitination have not been well studied.
UBE2Q1
is a novel E2 ubiquitin conjugating enzyme gene. Here, we investigated the effect of
UBE2Q1
overexpression on the level of p53 in the MDA-MB-468 breast cancer cell line as well as the interaction between
UBE2Q1
and p53. By using a lipofection method, the p53 mutated breast cancer cell line, MDA-MB-468, was transfected with the vector pCMV6-AN-GFP, containing
UBE2Q1
ORF. Western blot analysis was employed to verify the overexpression of
UBE2Q1
in MDA-MB-468 cells and to evaluate the expression level of p53 before and after cell transfection. Immunoprecipitation and
GST
pull-down protocols were used to investigate the binding of
UBE2Q1
to p53. We established MDA-MB-468 cells that transiently expressed a GFP fusion proteins containing
UBE2Q1
(GFP-UBE2Q1). Western blot analysis revealed that levels of p53 were markedly lower in
UBE2Q1
transfected MDA-MB-468 cells as compared with control MDA-MB-468 cells. Both in vivo and in vitro data showed that
UBE2Q1
co-precipitated with p53 protein. Our data for the first time showed that overexpression of UBE2Q1can lead to the repression of p53 in MDA-MB-468 cells. This repression of p53 may be due to its
UBE2Q1
mediated ubiquitination and subsequent proteasome degradation, a process that may involve direct interaction of UBE2Q1with p53.
...
PMID:UBE2Q1 in a Human Breast Carcinoma Cell Line: Overexpression and Interaction with p53. 2598 28